B

Baroness Cass (CB)

Speaking in the House of Lords on 22 October 2026

Debate

Puberty Blockers and Cross-sex Hormones

Contribution

My Lords, I declare my interests: I am the noble Baroness, Lady Cass, of the Cass review and an independent advisor to DHSC. As my noble friend said, the age at which under-16s can consent to medical interventions is determined by Gillick competence. Specifically in relation to puberty blockers, this issue has been tested through the courts through Bell v Tavistock. The original judgment was overturned on appeal because the court held that it was wrong to try to establish age-based criteria for competence, which must instead be assessed case by case in accordance with the Gillick principles. As noble Lords have already heard, because this is part of an approved research trial, children cannot consent anyway—they assent, and parents consent. So, with all due respect to the Minister, the only basis on which His Majesty’s Government can take a view on the question would be if they wanted to challenge the legal judgment or seek to change the law. As noble Lords have also heard, the routine commissioning of masculinising and feminising hormones is currently suspended. That is probably as far as one can go on the core question itself, but I understand the strength of feeling in the House, so I will say a little about children’s and young people’s gender services and how they are operating. The service currently includes five of the UK’s specialist children’s hospitals, and more centres are opening soon. It is staffed by some of the country’s most experienced professionals in children’s physical and mental health, and the chair of the network is a past president of RCPCH. To be absolutely clear, this is not a service driven by ideology. About 1,600 children and young people have been seen. They have a very wide range of problems, including depression, separation anxiety, social phobia, eating disorders and neurodiversity, and many of them have quite striking physical symptoms including pain, impaired mobility and functional impairment, which impacts on their ability to attend school, interact with peers and engage in normal physical activities. For some families there have been stresses such as domestic violence, parental mental health problems or parental death. A sizable minority of the patients are open to the safeguarding team—for example, because they suffered physical or sexual abuse, online grooming or exploitation, or because they are taking a range of unregulated medicines and hormones. So, the clinical team are providing a very wide range of therapeutic interventions aimed at improving physical and mental health and functional well-being. Sometimes, just addressing general health and nutrition and getting young people out of their bedroom and back into school to engage with peers is all that is needed for their gender distress to largely resolve and for them to re-engage with typical life, development and experience. I should say that we are following up all those children who do not get any medical pathway—or as many as will agree to consent—because one of the things I could not find out during my review, as they did not have the data, is what happened to the children and young people who did not go on a hormone pathway. At this point, fewer than 20 patients out of the 1,600 are even in the early stages of being considered for enrolment in the puberty blocker trial. As I reported previously, they are typically young people who have been socially transitioned since early childhood, and after 18 months of therapy, they still have absolutely no sense or concept of living in their biological gender. Decisions are taken after an extensive assessment and thorough multidisciplinary review, guided by considerations of the young person’s best interests. In other words, the clinicians have to feel that the risks of not enrolling them in the trial will outweigh the risks of enrolling them. In response to my noble friend’s remarks, we do not know of any definite irreversible effects of puberty blockers at this time; that is the whole point of the trial. These children are going to be extremely tightly monitored. The commitment is that they will be allowed to be on them for only two years in the first instance, with no automatic assumption that they will progress to masculinising or feminising hormones without further discussion and a further detailed assessment. The other commitment is that all the time they are on the puberty blockers, they are locked into two years’ further ongoing therapy within the service. For me, that has to be better than going out and getting some testosterone at the gym instead. The combined expertise in child health, mental health, safeguarding, clinical ethics and best interest decision-making within these specialist teams far exceeds that available to either House. For that reason, I have full confidence in their clinical judgments. I apologise to the noble Lord, Lord Winston, that I do not have the answers on epigenetics.

More from Baroness Cass (CB)

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.